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Knockdown of Annexin A1 induces apoptosis, causing 
G2/M arrest and facilitating phagocytosis activity in human 
leukemia cell lines
Annexin A1 (ANXA1) is an endogenous protein involved in 
the control of proliferation, cell cycle, phagocytosis, and 
apoptosis in several types of cancer. To investigate the  effects 
of ANXA1 knockdown in leukemia cells, transfection with 
specific ANXA1 siRNA was performed. Cell cycle and 
apoptosis were analyzed using flow cytometry and a mecha-
nism involving caspases and Bcl-2 was quantified using 
Western blotting. Phagocytosis activity was evaluated  using 
hematoxylin & eosin staining. The ANXA1 expression was 
significantly downregulated after the knockdown and 
apoptosis was induced in tested cells. The expression of 
caspase-9 and -3 increased in U937 and Jurkat cells respec-
tively. Bcl-2 expression was downregulated in K562 and 
Jurkat cells while upregulated in U937. The number of leu-
kemic cells arrested at the G2/M phase and the phagocytosis 
index were significantly increased in transfected cells. This 
suggests that ANXA1 knockdown might be a potential 
 approach in the therapeutic strategy for leukemia.
Keywords: Annexin A1, siRNA transfection, apoptosis, cell 
cycle, phagocytosis, leukemia
Annexin A1 is a 37 kDa protein with calcium and phospholipid-binding properties 
 involved in various physiological processes including inflammation, cell proliferation, 
 migration, differentiation, phagocytosis and apoptosis in multiple types of cancer. This cas-
cade of signaling pathways was activated through the association of ANXA1 with formyl 
peptide receptors (FPRs) (1). Recently, a study reported that ANXA1 level was significantly 
higher in leukemia cells (Jurkat, K562 and U937) compared to peripheral blood mononuclear 
cells (PBMC) (2). The role of Annexin A1 in the mechanisms of the mentioned processes is 
not completely clear, especially in leukemia.
Solito et al. reported that the treatment of human neutrophils with exogenous ANXA1 
stimulates apoptosis (3). A previous study showed that the overexpression of ANXA1 
indu ced apoptosis with caspase-3 activation in macrophages and bronchoalveolar cells (4, 
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 (Bcl-2) family (6). Caspases are produced in an inactive form called zymogens and are 
cleaved into active form during the apoptotic event. The activation of caspases, a family of 
cysteine-protease proteins and one of the hallmarks of apoptosis, can be categorized into 
initiator and effector caspases. The activation of initiator caspases (such as caspase-9 and 
-10) through the cleavage of aspartate (Asp) residue triggers the execution of effector 
 caspases (such as caspase-3 and -7). Extrinsic and intrinsic pathways, involving death 
 ligand-receptor and mitochondria respectively, are two major apoptosis pathways. The 
induction of apoptosis over the intrinsic pathway is associated with the release of cytochrome 
c from mitochondria that activates the initiator caspase, pro-caspase-9 (47 kDa) and is 
 activated by cleavage into the active form, caspase-9 (35 kDa). It then cleaves procaspase-3 
(35 kDa) into 19 kDa and 17 kDa subunits. Meanwhile, the extrinsic pathway involves the 
activation of caspase-8 or caspase-10 through the death ligand-receptor and the activation 
of initiator caspases subsequently activates the effector caspase, caspase-3 (7). The  common 
anti-cancer mechanism in cancer therapy is through induction of apoptosis (8). Bcl-2 is 
classified as an anti-apoptotic protein that is usually located in the outer membrane of 
mitochondria. The function of this protein is to protect mitochondrial membrane potential 
and prevent the release of cytochrome c or other pro-apoptotic proteins from the mito-
chondria. Localization of Bcl-2 in the inner membrane of mitochondria protects mito-
chondria from apoptosis and subsequently, resistance toward chemotherapeutic drugs as 
most of it is targeting mitochondria (9).
Besides, ANXA1 is able to alter cell cycle progression in few cancer cells including 
leukemia cells (10). A previous study reported that ANXA1 is involved in phagocytosis 
activity since knockdown of ANXA1 in RAW264.7 macrophages reduced the phagocytic 
activity (11). Therefore, the objective of the present study is to explore the effect of ANXA1 
knockdown on apoptosis, cell cycle arrest and phagocytosis activities in different types of 
leukemia. Thus, different leukemic cell lines (U937 cells, Jurkat cells, THP-1 and K562) were 
used as model cell lines for studying different types of leukemia.
EXPERIMENTAL
Cell cultures
The acute myeloid leukemia, U937 cells, acute lymphoblastic leukemia, Jurkat cells 
and acute monocytic leukemia, THP-1 cells were cultured in RPMI 1640 medium. Mean-
while, chronic myeloid leukemia, K562 cells, were grown in Iscove’s Modified Dulbecco’s 
medium, IMDM. The cultured media were enriched with 10 % of fetal bovine serum (FBS), 
1 % of penicillin-streptomycin. The cells were obtained from American Type Culture Col-
lection (Manassas, VA, USA).
Transfection with small interfering RNA (siRNA) of ANXA1
The Jurkat, U937 and K562 cells (1.5 × 105 cell mL–1) were transiently transfected with 
40, 80 and 100 nmol L–1 respectively of ANXA1 small interfering RNA (siRNA), (Silencer® 
Select Validated siRNA; siRNA ID s1381 Ambion, TX, USA) using the INTERFERin trans-
fection reagent (Polyplus-transfection Inc., France). Each of the experiments was done 
three times. Positive control of siRNA, fluorescein isothiocyanate, FITC conjugated  fluorescent 
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oligonucleotide (Block-it, Invitrogen) were analyzed using fluorescence microscopy to 
evaluate transfection efficiency 24 h post-transfection. The ANXA1 expression was quantified 
using Western blotting 72 h post-transfection.
Apoptosis assay
Post transfection, the ANXA1 knockdown cells were stained with Annexin V/propi-
dium iodide to quantify the percentage of apoptotic cells. The early marker of apoptosis is 
the externalization of phosphatidylserine (PtdSer) from the inner to the outer membrane. 
Annexin V was used due to its high affinity towards PtdSer, thus binding to PtdSer, 
 exposed on the outer membrane, served as a probe for detection. The cells were washed 
with cold PBS and incubated with a staining solution containing propidium iodide, FITC- 
-labeled Annexin V and binding buffer for 10 min. The percentage of viable, apoptotic and 
necrotic cells was assessed by FACSCanto II flow cytometer (Becton Dickinson, USA).
Western blotting
Western blotting was conducted to determine the protein expression level of ANXA1 
and apoptosis proteins post knockdown. All of the proteins were extracted with RIPA lysis 
buffer (MERCK) and quantified using Bradford protein assay (Bio-Rad, USA). The same 
amount of protein was separated using 10 % SDS-polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to polyvinylidene fluoride (PVDF) membranes (Merck, Germany) and 
blocked with 5 % milk in Tris-buffered Saline, 0.1 % Tween 20 (TBST) for 1 h at room tem-
perature. The membranes were incubated overnight with antibodies of ANXA1, caspase-1, 
caspase-3, caspase-9, Bcl-2, and β-actin (1:1000) as a loading control (Cell Signaling Tech-
nology, USA). Then, membranes were washed, incubated for 1 h with secondary anti-rabbit 
horseradish peroxide (HRP)-conjugated antibody (1:5000) (Cell Signaling Technology) and 
visualized using the enhanced chemiluminescence (ECL) detection kit on ChemiDoc MP 
System (Bio-Rad, USA).
Cell cycle assay
Cells were washed twice with cold phosphate-buffered saline (PBS) and fixed in cold 
70 % ethanol. Post 2 h of fixation process, cells were rinsed with PBS, stained for 30 min 
with propidium iodide buffer containing 0.2 mg mL–1 of propidium iodide, 0.2 mg mL–1 of 
RNase A and PBS in the darkroom. The cell cycle phases were conducted using a FACS-
Canto II flow cytometer and the result was analyzed using ModFit LT software (Becton 
Dickinson, USA). Propidium iodide is a DNA-intercalating agent used to analyze DNA 
content in the cell cycle.
Phagocytosis assay
THP-1 cells were differentiated into macrophages for 48 h after treated with 20 ng 
mL–1 of phorbol 12-myristate 13-acetate (PMA). The non-transfected and transfected cells 
were co-cultured with macrophages for 3 h and stained with hematoxylin and eosin. The 
percentage of phagocytosis and phagocytosis index were calculated using the equations 
(1) and (2):
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 Percentage of phagocytosis (%) = 
b
a
 × 100  (1)




where a is the number of macrophages, 200, b is the number of macrophages that engulfed 
apoptotic cells and c is the number of apoptotic cells engulfed by macrophages.
Statistical analysis
All results are presented as mean and standard error mean, SEM and were statisti-
cally analyzed using t-test by GraphPad Prism 5 Software (CA, USA). The targeted protein 
bands’ intensities detected by Western blotting were normalized to β-actin. Differences 
were considered significant when p values less than 0.05.
RESULTS AND DISCUSSION
Knockdown of ANXA1 expression using siRNA
In order to determine the ANXA1 effects on cell apoptosis, cell cycle arrest and phago-
cytosis activities in leukemia cells, knockdown using ANXA1 siRNA transfection was 
carried out. Firstly, the transfection efficiency was determined using BLOCK-iT Fluores-
cent control siRNA. After 24 h of transfection, the knockdown cells were observed using 
a fluorescent microscope. Fig. 1a shows the image of transfected leukemia cells. The red 
fluorescence cells represent successfully transfected cells with BLOCK-IT siRNA. Cells 
that do not emit any fluorescent light were considered non-transfected cells. The ANXA1 
expression of transfected cells was detected using Western blot. The results presented in 
the figure below showed significant downregulation of ANXA1 expression in the ANXA1 
transfected cell, compared to the negative control, non-transfected cell post-transfection. 
The ANXA1 expression of transfected Jurkat, K562 and U937 was significantly decreased 
by 70, 69 and 63 % as compared to non-transfected cells, respectively. These results demon-
strated that ANXA1 expression successfully decreased in leukemia cells. Thus, the ANXA1 
transfected cells were assessed for apoptosis, cell cycle, and phagocytosis assay.
Knockdown of ANXA1 with siRNA induces apoptosis and necrosis
To determine the effect of ANXA1 knockdown in affecting apoptotic cells, cells were 
measured using flow cytometry. The percentage of viable, apoptotic, and necrotic cells was 
quantified using flow cytometry. The distribution of apoptotic cells was determined as 
those in early apoptosis (Quadrant 4 (Q4), lower right quadrant), late apoptosis (Quadrant 
2 (Q2), upper right quadrant) and necrotic cells in Quadrant 1 (Q1), upper left quadrant. 
Fig. 2 showed that the percentage of viable cells in quadrant 3 (Q3) decreased significantly 
in K562 cells. The relative percentage change of apoptotic cells was significantly increased 
in the transfected Jurkat (138.9 %), K562 (89.7 %) cells with p < 0.05 for both cell lines and 
U937 (49.4 %) cells with p < 0.01 in comparison to its respective non-transfected cells. 
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 Necro sis is marked by nonspecific swelling of cells and disruption on cell membrane 
 integrity. This will cause externalization of cell content to the outer environment that can 
cause inflammation. ANXA1 knockdown significantly increased the relative percentage 
change of necrotic cells (617.9 %) with p < 0.05 in K562 cells.
In this study, suppression of ANXA1 in Jurkat, K562 and U937 cells caused significant 
apoptosis. These indicated that suppression of ANXA1 expression induced apoptosis in 
Jurkat, K562, and U937 cells. This finding was supported by Chen et al. who revealed that 
ANXA1 knockdown inhibits cell proliferation and induces apoptosis in human T cell leu-
kemia virus type I, HTLV-I-transformed T cell (12). The previous research findings have 
shown that ANXA1 is involved in the apoptosis process; some studies suggested ANXA1 
as a pro-apoptotic protein, whereas others demonstrated that ANXA1 acts as an anti-apop-
totic protein in certain cancer cells. Wu et al. reported that a high level of ANXA1 inhibits 
Fig. 1. a) The transfected cells (coloured red) were observed under a fluorescence microscope (100× 
magnification). b) The quantification of ANXA1 protein expression using Western blotting analysis 
showed that ANXA1 protein expression was downregulated in the transfected cell (T) compared to 
the non-transfected cell (NT). β-actin was used as a loading control. Data are presented as mean ± 
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Fig. 2. a) A dot plot of the cell distribution percentage after ANXA1 knockdown. Q1: Necrotic cells, 
Q2: Late apoptotic cells, Q3: Viable cells, Q4: Early apoptotic cells. b) The effects of ANXA1 knock-
down on cell viability, apoptosis and necrosis in Jurkat, K562 and U937 cells. T: transfected cells, NT: 
non-transfected cells. The value expressed as mean ± standard error mean (SEM); n = 3, * (p < 0.05) 
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apoptosis and might protect them against immune surveillance in human leukemic cells 
(13). Moreover, Jia and colleagues found that high ANXA1 expression was reported in 
multiple myeloma cells, NCI-H929 and RPMI8226 and after silencing of ANXA1 in both 
cells, apoptosis was induced (14). The suppression of ANXA1 protein might cause disrup-
tion in the normal condition of leukemic cells and eventually caused cell death. This indi-
cated that ANXA1 might serve as an oncogene protein in these types of leukemia cells. 
Even though the percentage of necrotic cells decreased non significantly in transfected 
U937 cells, this is probably because of the phagocytic ability possessed by this cell line as 
monocytes are classified as professional phagocytes (15). To further confirm the involve-
ment of ANXA1 in apoptosis, the molecular mechanism study was conducted.
Mechanism of apoptosis in cells transfected with siRNA for ANXA1
To evaluate the molecular mechanism of apoptosis through the activation of caspases, 
Western blotting was performed. Knockdown of ANXA1 significantly induced cell death 
and this is probably related to the increase of pro-caspase-3 and pro-caspase-9 expression. 
As shown in Fig. 3, transfected cells cause an increase of the initiator caspase, pro-cas-
pase-9 expression in U937 but a decrease in K562 cells. Meanwhile, the effector caspase, 
pro-caspase-3 expression was increased in Jurkat and decreased in U937 cells. However, 
no caspase cleavage was observed. Bcl-2 expression showed upregulation in U937 but 
downregulated in K562 cells. Caspase-1 is an enzyme involved in the activation of the pro-
inflammatory cytokine, however, western blotting showed an incresed procaspase-1 level 
in all cells after ANXA1 knockdown.
The Western blotting technique was performed to study the molecular mechanism 
involved in the induction of apoptosis after ANXA1 knockdown. Based on this study, the 
expression of pro-caspase-3 and pro-caspase-9 showed a slight increase in certain cells 
however no cleavage of these caspases was observed. Feng et al. demonstrated that silenc-
ing of ANXA1 reduced apoptosis by upregulating Bcl-2 and procaspase-3 levels while 
downregulating the expression of cleaved caspase-3 in trophoblasts from preeclampsia 
rat’s placenta tissue (16). The cleavage of caspase-9 and caspase-3 in this study was not 
observed probably due to approximately 10 min of caspase activation when there was a 
trigger of cell destruction. The execution of apoptosis begins with permeabilization of the 
mitochondrial membrane, the release of pro-apoptotic proteins into the cytosol then acti-
vates caspases (17). Induction of apoptosis in U937 cells may involve an intrinsic pathway 
with an increased level of pro-caspase-9 and decreased level of pro-caspase-3 expression after 
ANXA1 knockdown. Meanwhile, knockdown of ANXA1 in K562 cells caused a decrease in 
procaspase-9 and an increase in procaspase-3 expression that induced apoptosis through 
the extrinsic pathway. Likewise, in Jurkat cells, knockdown of ANXA1  increased pro-
caspase-3, caused no change in pro-caspase-9 expression and induced apoptosis through 
the extrinsic pathway that may be involved in the activation of caspase-8 or caspase-10.
This study proves that Bcl-2 expression in K562 cells showed a slight reduction com-
pared to non-transfected cells. The decrease of Bcl-2 expression with no disruption of mito-
chondrial membrane potential (MMP) might be caused by a significant decrease of pro- 
-caspase-9 expression in K562 cells. On the contrary, in U937 cells apoptosis occurs despite 
an increase in Bcl-2 expression levels. This may due to the increase of pro-caspase-9 
 expression because there is a disruption of MMP where Bcl-2 takes action in protecting MMP 
and preventing apoptosis. The previous study reported that Bcl-2 expression is overexpressed 
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Fig. 3. Expression of caspases -9, -3, -1 and Bcl-2 proteins in non-transfected (NT) and transfected (T) 
cells were quantified using Western blotting. The value are expressed as mean ± standard error mean 
(SEM), n = 3, * (p < 0.05) when compared with non-transfected cells. Full-length blots are presented in 
Supplementary Data Fig. 3.
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Fig. 4. a) Flow cytometry analysis and b) Bar chart of cell cycle distribution after ANXA1 knockdown 
in transfected (T) Jurkat, K562 and U937 cells compared to non-transfected cells (NT). Data are pre-
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in leukemic cancer such as acute myeloid leukemia (9). This suggests why leukemic cells 
are resistant to chemotherapeutic agents. Prior activation of caspase-9, apoptotic stimuli 
causes the activation of pro-apoptotic protein such as Bax or Bak and release of apoptosis 
promoting factors such as cytochrome c, Smac/DIABLO and apoptosis-inducing factor (AIF). 
This finding was supported by the previous study done by Moore and Letai which showed 
that the overexpression of Bcl-2 did not prevent the cells from undergoing apoptosis (18).
This finding showed an increase of pro-caspase-1 expression after ANXA1 knock 
-down in all leukemic cells, however, no cleavage of caspase-1 was observed. Knockdown 
of ANXA1 halted the ability of ANXA1 to act as an anti-inflammatory protein which in-
creased pro-caspase-1 expression due to inflammation. Caspase-1 activation cleaved pro-
inflammatory cytokines (pro-IL-1β and pro-IL-18) into active forms and activated the ef-
fector caspase, caspase-7 as well (19). Caspase-1 involved in pro-inflammatory cytokines 
activation during inflammation and ANXA1 was first discovered as an endogenous anti-
inflammatory glucocorticoid-inducible protein by inhibiting cytosolic phospholipase A2 
(cPLA_2), cyclooxygenase-2 (COX2) and consequently suppressing prostaglandin and 
leuko triene production (20). Activation of caspase-1 in cultured mouse cortical neurons 
triggers BH3-interacting domain (Bid) cleavage into truncated Bid, tBid and activates a 
mitochondrial pathway that induces apoptosis (21).
Knockdown of ANXA1 induces cell cycle arrest at the G2/M phase
Cell cycle arrest is an important process for repairing damaged DNA before entering 
into another phase. To determine the effect of ANXA1 suppression in affecting cell cycle 
progression, staining with propidium iodide and analysis using flow cytometry was con-
ducted. After transfection, ANXA1 knockdown resulted in a significant reduction in G0/
G1 phase and a significant increase in the G2/M phase at transfected cells in comparison 
to non-transfected cells. Fig. 4 showed that knockdown of ANXA1 caused the relative 
percentage change of the G2/M phase to increase significantly by 85.1 % for Jurkat, 100.7 % 
for K562 with p < 0.05 for both cell lines and 15.4 % for U937 with p < 0.01 compared to its 
non-transfected cells. This can be observed as a significant decrease in the relative percent-
age change of the G0/G1 phase with p < 0.05 for 3 cell types tested; a increase by 21.5 % for 
Jurkat cell, 26.3 % for K562 cell and 5.1 % for U937 cell compared to respective non-trans-
fected cells. Therefore, this causes the cell cycle arrest at the G2/M phase in Jurkat, K562, 
and U937 cells.
Results obtained showed that after ANXA1 knockdown, cell cycle progression was 
arrested at the G2/M phase with a decrease in the cell population at the G0/G1 phase in all 
cells. This suggests that without ANXA1, there is DNA damage causing cell cycle arrest to 
occur at the G2/M phase. This finding was supported by the previous study done by Liu 
et al. who reported that ANXA1 silencing caused cell cycle arrest at the G0/G1 phase in 
MIA PaCa-2 and BxPC3, human pancreatic cells (22). Besides, Li and colleagues showed 
that an increase in ANXA1 caused arrest at the G0/G1 phase and supported this finding 
which showed ANXA1 knockdown caused the G2/M arrest (23).
Effect of ANXA1 knockdown on phagocytosis activity
To determine the effect of ANXA1 knockdown on phagocytosis activity, hematoxylin-
eosin staining was conducted. The percentage of phagocytosis was determined as the 
number of macrophages that actively phagocytose. Meanwhile, the phagocytosis index 
(PI) was defined as the number of apoptotic cells engulfed by each phagocytically active 
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macrophage. Results shown in Fig. 5 describe that the knockdown of ANXA1 significantly 
increased the relative percentage change of phagocytosis in Jurkat (42.9 %, p < 0.05), K562 
(42.0 %, p < 0.05) and U937 (35.6 %, p < 0.05) compared to its non-transfected cell. Phagocy-
tosis index (PI) of ANXA1 siRNA Jurkat (2.75 ± 0.17, p < 0.05), K562 (5.43 ± 0.88, p < 0.05) and 
U937 (4.81 ± 0.48, p < 0.05) cells is significantly increased compared to non-transfected cell. 
These results showed an increase in the percentage of phagocytosis and PI in ANXA1 
knockdown cells.
Removal of apoptotic cells by phagocytosis is a crucial process in inflammation pre-
vention. Signals displayed by apoptotic cells, such as ‘find-me’ and ‘eat-me’ signals, draw 
the attention of a macrophage to phagocyte them (24). The results showed the efficiency of 
macrophage in removing damaged or apoptotic cells were increased after ANXA1 knock-
down. Knockdown of ANXA1 induced apoptosis and caused apoptotic cells to display 
Fig. 5. a) Haematoxylin-eosin staining of cells with arrows indicating apoptotic cells engulfed by 
macrophages. (100× magnification). b) The percentage of phagocytosis and phagocytosis index (PI) 
are significantly higher in transfected cells (T) compared to non-transfected cells (NT). Data are 
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‘eat-me’ signals such as phosphatidylserine (PtdSer), fractalkine, sphingosine-1-phosphate 
(S1P) and lysophosphatidylcholine (LPC); which are released from apoptotic and necrotic 
cells to attract phagocytes to the apoptotic cell (25). Therefore, signals produced by both 
apoptotic and necrotic cells attract macrophages to engulf them.
CONCLUSIONS
This finding concludes that ANXA1 is an important protein in human leukemia cells 
and knockdown of ANXA1 presents the potential treatment strategy due to the ability to 
induce apoptosis, cause cell cycle arrest and phagocytosis in leukemia cells. Besides, the 
results indicated that ANXA1 functions as an anti-apoptotic protein and ANXA1 knock-
down disrupts normal conditions in cancer cells causing cell cycle arrest and apoptosis. 
The unique characteristic of ANXA1 knockdown in inducing apoptosis through the dif-
ferent mechanisms for each cell line convinces that this protein exhibits different effects 
based on cell-type behavior; an intrinsic pathway for U937 cell and an extrinsic pathway 
for Jurkat and K562 cells that contribute more information about this protein. These find-
ings can contribute to further understanding of ANXA1 role in human leukemic cell lines.
Acknowledgement. – This project has been funded by the Ministry of Higher Education for Fun-
damental Research Grant Scheme (FRGS), FRGS/1/2015/SKK09/UKM/02/3. The authors acknowledge 
and thank the Faculty of Health Science, UKM for the BD FacsCanto II flow cytometry.
REFERENCES
 1.  R. Belvedere, V. Bizzarro, A. Popolo, F. Dal Piaz, M. Vasaturo, P. Picardi, L. Parente and A. Pe-
trella, Role of intracellular and extracellular annexin A1 in migration and  invasion of human 
pancreatic carcinoma cells, BMC cancer 14 (2014) 961–975; https://doi.org/10.1186/1471-2407-14-961
 2.  A. Sabran, E. Kumolosasi and I. Jantan, Effects of annexin A1 on apoptosis and cell cycle arrest in 
human leukemic cell lines, Acta Pharm. 69 (2019) 75–86; http://doi.org/10.2478/acph-2019-0005
 3.  E. Solito, C. De Coupade, S. Canaider, N. J. Goulding and M. Perretti, Transfection of annexin 1 in 
monocytic cells produces a high degree of spontaneous and stimulated apoptosis associated with 
caspase-3 activation, Br. J. Pharmacol. 133 (2001) 217–228; https://doi.org/10.1038/sj.bjp.0704054
 4.  C. W. D’Acunto, B. Fontanella, M. Rodriquez, M. Taddei, L. Parente and A. Petrella, Histone 
deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis 
through up-regulation of Annexin A1, Cancer Lett. 295 (2010) 85–91; https://doi.org/10.1016/j.can-
let.2010.02.016
 5.  R. Debret, H. El Btaouri, L. Duca, I. Rahman, S. Radke, B. Haye, J. M. Sallenave and F. Antonicelli, 
Annexin A1 processing is associated with caspase-dependent apoptosis in BZR cells, FEBS Lett. 
546 (2003) 195–202; https://doi.org/10.1016/s0014-5793(03)00570-2
 6.  Y. Feng, J. Wu, X. Feng, D. Tao, J. Hu, J. Qin, X. Li, W. Xiao, K. Gardner, S. I. V. Judge, Q. Q. Li and 
J. Gong, Timing of apoptosis onset depends on cell cycle progression in peripheral blood lympho-
cytes and lymphocytic leukemia cells, Oncol. Rep. 17 (2007) 1437–1444; https://doi.org/10.3892/
or.17.6.1437
 7.  S. Fulda and K. M. Debatin, Extrinsic versus intrinsic apoptosis pathways in anticancer chemo-
therapy, Oncogene 25 (2006) 4798–4811; https://doi.org/10.1038/sj.onc.1209608
121
M. Hasan et al.: Knockdown of Annexin A1 induces apoptosis, causing G2/M arrest and facilitating phagocytosis activity in human 
leukemia cell lines, Acta Pharm. 72 (2022) 109–122.
 
 8.  S. Inoue, G. Browne, G. Melino and G. M. Cohen, Ordering of caspases in cells undergoing apop-
tosis by the intrinsic pathway, Cell Death Differ. 16 (2009) 1053–1061; https://doi.org/10.1038/
cdd.2009.29
 9.  E. Tothova, M. Fricova, N. Stecova, A. Kafkova and A. Elbertova, High expression of Bcl-2 protein 
in acute myeloid leukemia cells is associated with poor response to chemotherapy, Neoplasma 49 
(2002) 141–144; https://pubmed.ncbi.nlm.nih.gov/12097997
10.  A. Petrella, C. W. D’Acunto, M. Rodriquez, M. Festa, A. Tosco, I. Bruno, S. Terracciano, M. Taddei, 
L. G. Paloma and L. Parente, Effects of FR235222, a novel HDAC inhibitor, in proliferation and 
apoptosis of human leukaemia cell lines: role of annexin A1, Eur. J. Cancer 44 (2008) 740–749; 
https://doi.org/10.1016/j.ejca.2008.01.023
11.  D. M. Patel, S. F. Ahmad, D. G. Weiss, V. Gerke and S. A. Kuznetsov, Annexin A1 is a new func-
tional linker between actin filaments and phagosomes during phagocytosis, J. Cell Sci. 124 (2011) 
578–588; https://doi.org/10.1242/jcs.076208
12.  Z. Chen, E. Yoshihara, A. Son, Y. Matsuo, H. Masutani, K. Sugie, M. Maeda and J. Yodoi, Differ-
ential roles of Annexin A1 (ANXA1/lipocortin-1/lipomodulin) and thioredoxin binding protein-2 
(TBP-2/VDUP1/TXNIP) in glucocorticoid signaling of HTLV-I-transformed T cells, Immunol. Lett. 
13 (2010) 11–18; https://doi.org/10.1016/j.imlet.2010.04.003
13.  Y. L. Wu, X. R. Jiang, D. M. Lillington, A. C. Newland and S. M. Kelsey, Upregulation of lipocortin 
1 inhibits tumour necrosis factor-induced apoptosis in human leukaemic cells: a possible mecha-
nism of resistance to immune surveillance, Br. J. Haematol. 111 (2000) 807–816; https://onlinelibrary.
wiley.com/doi/pdf/10.1111/j.1365-2141.2000.02397.x
14.  C. Jia, D. Kong, Y. Guo, L. Li and L. Quan, Enhanced antitumor effect of combination of annexin 
A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo, Biochem. 
Biophis. Res. Commun. 505 (2018) 720–725; https://doi.org/10.1016/j.bbrc.2018.09.140
15.  E. Uribe-Querol and C. Rosales, Control of phagocytosis by microbial pathogens, Front. Immunol. 
8 (2017) 1–23; https://doi.org/10.3389/fimmu.2017.01368
16.  J. Feng, X. Wang, H. Li, L. Wang and Z. Tang, Silencing of Annexin A1 suppressed the apoptosis 
and inflammatory response of preeclampsia rat trophoblasts, Int. J. Mol. Med. 42 (2018) 3125–3134; 
https://doi.org/10.3892/ijmm.2018.3887
17.  D. R. Green, Apoptotic pathways: Ten minutes to dead, Cell. 121 (2005) 671–674; https://doi.org/ 
10.1016/j.cell.2005.05.019
18.  V. D. Moore and A. Letai, Rational design of therapeutics targeting the BCL-2 family: are some 
cancer cells primed for death but waiting for a final push? Adv. Exp. Med. Biol. 615 (2008) 159–175; 
https://doi.org/10.1007/978-1-4020-6554-5_8
19.  L. Franchi, T. Eigenbrod, R. Muñoz-Planillo and G. Nuñez, The inflammasome: a caspase-1-acti-
vation platform that regulates immune responses and disease pathogenesis, Nature Immunol. 10 
(2009) 241–247; https://www.nature.com/articles/ni.1703
20.  N. Vergnolle, P. Pagès, R. Guimbaud, S. Chaussade, L. Buéno, J. Escourrou and C. Comera, An-
nexin 1 is secreted in situ during ulcerative colitis in humans, Inflamm. Bowel Dis. 10 (2004) 584–
592; https://doi.org/10.1097/00054725-200409000-00013
21.  A. Denes, G. Lopez-Castejon and D. Brough, Caspase-1: is IL-1 just the tip of the ICEberg? Cell 
Death Dis. 3 (2012) e338-e346; https://doi.org/10.1038/cddis.2012.86
22.  Q. H. Liu, M. L. Shi, J. Bai and J. N. Zheng, Identification of ANXA1 as a lymphatic metastasis and 
poor prognostic factor in pancreatic ductal adenocarcinoma, Asian Pac. J. Cancer Prev. 16 (2015) 
2719–2724; https://doi.org/10.7314/apjcp.2015.16.7.2719
23.  G. Li, S. He, L. Chang, H. Lu, H. Zhang, H. Zhang and J. Chiu, GADD45α and annexin A1 are 
involved in the apoptosis of HL-60 induced by resveratrol, Phytomedicine 18 (2011) 704–709; https://
doi.org/10.1016/j.phymed.2010.11.015
122
M. Hasan et al.: Knockdown of Annexin A1 induces apoptosis, causing G2/M arrest and facilitating phagocytosis activity in human 
leukemia cell lines, Acta Pharm. 72 (2022) 109–122.
 
24.  S. Y. Park and I. S. Kim, Engulfment signals and the phagocytic machinery for apoptotic cell clear-
ance, Exp. Mol. Med. 49 (2017) e331-e340; https://doi.org/10.1038/emm.2017.52
25.  I. K. H. Poon, C. D. Lucas, A. G. Rossi and K. S. Ravichandran, Apoptotic cell clearance: basic biol-
ogy and therapeutic potential, Nat. Rev. Immunol. 14 (2014) 166–180; https://doi.org/10.1038/nri3607
